Medigene AG confirmed its financial forecast for 2022 published in the Group Management's Discussion and Analysis 2021 and continues to expect revenues of EUR 23 million - EUR 28 million.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
1.165 EUR | +3.56% |
|
+2.14% | -21.64% |
06-27 | Medigene Presents Efficient 6-Day TCR-T Therapy Production Process with High Stemness | CI |
05-21 | Medigene, BioNTech Extend Cancer Immunotherapy Partnership | MT |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.64% | 35.61M | |
+16.44% | 122B | |
+18.94% | 113B | |
+18.54% | 26.22B | |
-25.37% | 19.01B | |
-20.02% | 15.71B | |
-20.20% | 15.22B | |
-47.37% | 14.72B | |
+59.91% | 14.58B | |
+4.35% | 13.84B |
- Stock Market
- Equities
- MDG1 Stock
- News Medigene AG
- Medigene AG Confirms Revenue Forecast for 2022